Literature DB >> 28707119

Response to the letter by Adams and Kwee, entitled: "Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma".

Elif Hindié1,2, Charles Mesguich3, Krimo Bouabdallah4, Noël Milpied4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28707119     DOI： 10.1007/s00259-017-3773-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  30 in total

1.  18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma.

Authors:  Juliano J Cerci; Luís F Pracchia; Camila C G Linardi; Felipe A Pitella; Dominique Delbeke; Marisa Izaki; Evelinda Trindade; José Soares; Valeria Buccheri; José C Meneghetti
Journal:  J Nucl Med       Date:  2010-08-18       Impact factor: 10.057

2.  (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging.

Authors:  Gerard Moulin-Romsee; Elif Hindié; Xavier Cuenca; Pauline Brice; Didier Decaudin; Myriam Bénamor; Josette Brière; Marcela Anitei; Jean-Emmanuel Filmont; David Sibon; Eric de Kerviler; Jean-Luc Moretti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-04       Impact factor: 9.236

3.  Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

Authors:  Robert Chen; Pier Luigi Zinzani; Michelle A Fanale; Philippe Armand; Nathalie A Johnson; Pauline Brice; John Radford; Vincent Ribrag; Daniel Molin; Theodoros P Vassilakopoulos; Akihiro Tomita; Bastian von Tresckow; Margaret A Shipp; Yinghua Zhang; Alejandro D Ricart; Arun Balakumaran; Craig H Moskowitz
Journal:  J Clin Oncol       Date:  2017-04-25       Impact factor: 44.544

4.  Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma.

Authors:  Hugo J A Adams; Thomas C Kwee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10       Impact factor: 9.236

5.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

6.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Authors:  Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

7.  Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group.

Authors:  Peter Borchmann; Heinz Haverkamp; Andreas Lohri; Ulrich Mey; Stefanie Kreissl; Richard Greil; Jana Markova; Michaela Feuring-Buske; Julia Meissner; Ulrich Dührsen; Helmut Ostermann; Ulrich Keller; Georg Maschmeyer; Georg Kuhnert; Markus Dietlein; Carsten Kobe; Hans Eich; Christian Baues; Harald Stein; Michael Fuchs; Volker Diehl; Andreas Engert
Journal:  Lancet Oncol       Date:  2017-02-22       Impact factor: 41.316

8.  Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma.

Authors:  Tarec Christoffer El-Galaly; Francesco d'Amore; Karen Juul Mylam; Peter de Nully Brown; Martin Bøgsted; Anne Bukh; Lena Specht; Annika Loft; Victor Iyer; Karin Hjorthaug; Anne Lerberg Nielsen; Ilse Christiansen; Charlotte Madsen; Hans-Erik Johnsen; Martin Hutchings
Journal:  J Clin Oncol       Date:  2012-11-13       Impact factor: 44.544

Review 9.  18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review.

Authors:  Teruhiko Terasawa; Takashi Nihashi; Tomomitsu Hotta; Hirokazu Nagai
Journal:  J Nucl Med       Date:  2007-12-12       Impact factor: 10.057

10.  Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.

Authors:  Anas Younes; Armando Santoro; Margaret Shipp; Pier Luigi Zinzani; John M Timmerman; Stephen Ansell; Philippe Armand; Michelle Fanale; Voravit Ratanatharathorn; John Kuruvilla; Jonathon B Cohen; Graham Collins; Kerry J Savage; Marek Trneny; Kazunobu Kato; Benedetto Farsaci; Susan M Parker; Scott Rodig; Margaretha G M Roemer; Azra H Ligon; Andreas Engert
Journal:  Lancet Oncol       Date:  2016-07-20       Impact factor: 41.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.